Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Melanoma

  Free Subscription


Articles published in Melanoma Res

Retrieve available abstracts of 329 articles:
HTML format



Single Articles


    February 2025
  1. BEITNER A, Abu-Abeid A, Dayan D, Gat A, et al
    Patterns of expression and prognostic implication of glycoprotein nonmetastatic protein B (GPNMB) expression in sentinel lymph nodes of melanoma patients.
    Melanoma Res. 2025 Feb 14. doi: 10.1097/CMR.0000000000001019.
    PubMed     Abstract available


  2. AMRANE K, Le Noac'h P, Hemon P, Abgral R, et al
    MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.
    Melanoma Res. 2025 Feb 12. doi: 10.1097/CMR.0000000000001022.
    PubMed     Abstract available


  3. GONZALEZ-BARRALLO I, Castellon Rubio VE, Medina J, Espana Fernandez S, et al
    Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study.
    Melanoma Res. 2025 Feb 7. doi: 10.1097/CMR.0000000000001020.
    PubMed     Abstract available


  4. KERKOUR T, Meijers RWJ, Hollestein LM, Jansen AML, et al
    Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases.
    Melanoma Res. 2025 Feb 6. doi: 10.1097/CMR.0000000000001024.
    PubMed     Abstract available


  5. TAS F, Erturk K
    Brain metastases during follow-up of patients with resected cutaneous melanoma.
    Melanoma Res. 2025 Feb 4. doi: 10.1097/CMR.0000000000001026.
    PubMed     Abstract available


  6. BHATT KA, Vaynrub AJ, Cham J, Iyer SG, et al
    Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia.
    Melanoma Res. 2025 Feb 4. doi: 10.1097/CMR.0000000000001025.
    PubMed     Abstract available


  7. SHEN YC, Huang YL, Kang YN, Chiu WK, et al
    Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlled trials.
    Melanoma Res. 2025;35:60-66.
    PubMed     Abstract available


    January 2025
  8. ANGELL CD, Sun SH, Lapurga G, Benner B, et al
    A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.
    Melanoma Res. 2025 Jan 29. doi: 10.1097/CMR.0000000000001023.
    PubMed     Abstract available


  9. CHEN L, Cai B, Ni X, Lin Q, et al
    Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety.
    Melanoma Res. 2025 Jan 28. doi: 10.1097/CMR.0000000000001021.
    PubMed     Abstract available


  10. BASSI V, Apuzzi V, Vanella V, Facchini BA, et al
    SIAD onset in a patient affected by metastatic melanoma treated with immune checkpoint inhibitors: the role of nivolumab treatment.
    Melanoma Res. 2025 Jan 7. doi: 10.1097/CMR.0000000000001017.
    PubMed    


  11. POZUELO-RUIZ M, de Unamuno-Bustos B, Palacios-Diaz RD, Blanes-Martinez MDM, et al
    Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals.
    Melanoma Res. 2025 Jan 7. doi: 10.1097/CMR.0000000000001018.
    PubMed     Abstract available


    December 2024
  12. AL-NAESAN I, Krepper D, Sparano F, Sztankay M, et al
    Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results.
    Melanoma Res. 2024 Dec 11. doi: 10.1097/CMR.0000000000001014.
    PubMed     Abstract available


  13. LEIBOVIT-REIBEN Z, Godfrey H, Jedlowski P, Thiede R, et al
    Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.
    Melanoma Res. 2024 Dec 6. doi: 10.1097/CMR.0000000000001015.
    PubMed     Abstract available


  14. ESMAELI B, Ogden T, Nichols M, Lu T, et al
    Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma.
    Melanoma Res. 2024 Dec 6. doi: 10.1097/CMR.0000000000001016.
    PubMed     Abstract available


  15. WITTEVEEN SJ, Klop WMC, van Dijk-de Haan MC, Karssemakers LHE, et al
    Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I-II.
    Melanoma Res. 2024 Dec 3. doi: 10.1097/CMR.0000000000001013.
    PubMed     Abstract available


  16. HORISAKI K, Yoshikawa S, Omata W, Tsutsumida A, et al
    Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study.
    Melanoma Res. 2024 Dec 3. doi: 10.1097/CMR.0000000000001012.
    PubMed     Abstract available


  17. BURSHTEIN J, Shah M, Zakria D, Rigel D, et al
    The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio.
    Melanoma Res. 2024;34:550-552.
    PubMed    


  18. ARJUNAN A, Wardrop M, Malek MM, Davit AJ 3rd, et al
    Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients.
    Melanoma Res. 2024;34:544-548.
    PubMed     Abstract available


    November 2024
  19. NIU L, Liu S, Shen J, Chang J, et al
    ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells.
    Melanoma Res. 2024 Nov 26. doi: 10.1097/CMR.0000000000001011.
    PubMed     Abstract available


  20. MACAIRE C, Lefevre W, Dalac S, Montaudie H, et al
    Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
    Melanoma Res. 2024 Nov 11. doi: 10.1097/CMR.0000000000000973.
    PubMed     Abstract available


    October 2024
  21. ZHENG L, Susanto AK, Soyer HP, Janda M, et al
    Psychosocial wellbeing in people with melanoma in-situ: a systematic review.
    Melanoma Res. 2024 Oct 10. doi: 10.1097/CMR.0000000000001007.
    PubMed     Abstract available


  22. KREUZ M, de Moraes FCA, Sano VKT, Westphal Filho FL, et al
    Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis.
    Melanoma Res. 2024 Oct 8. doi: 10.1097/CMR.0000000000001006.
    PubMed     Abstract available


  23. CAMPILLO P, Kesler A, Ramirez CA, Ramirez CJ, et al
    International incidence of melanoma in heart transplant recipients: a meta-analysis.
    Melanoma Res. 2024 Oct 7. doi: 10.1097/CMR.0000000000001008.
    PubMed     Abstract available


  24. PAOLINO G, Podo Brunetti A, De Rosa C, Cantisani C, et al
    Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma.
    Melanoma Res. 2024 Oct 4. doi: 10.1097/CMR.0000000000001003.
    PubMed     Abstract available



  25. Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum.
    Melanoma Res. 2024;34:473.
    PubMed    


  26. MATTIUZZI C, Lippi G
    The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic.
    Melanoma Res. 2024;34:472.
    PubMed    


    September 2024
  27. NACCHIERO E, Giotta M, Robusto F, Metta ME, et al
    The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease.
    Melanoma Res. 2024 Sep 25. doi: 10.1097/CMR.0000000000000999.
    PubMed     Abstract available


  28. STAWIARZ M, Hoang MP, Kowalik A
    High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma.
    Melanoma Res. 2024 Sep 18. doi: 10.1097/CMR.0000000000001005.
    PubMed     Abstract available


  29. MCKECHNIE T, Talwar G, Grewal S, Wang A, et al
    The impact of statins on melanoma survival: a systematic review and meta-analysis.
    Melanoma Res. 2024 Sep 12. doi: 10.1097/CMR.0000000000001001.
    PubMed     Abstract available


    August 2024
  30. STOFF R, Markovic SN, McWilliams RR, Kottschade LA, et al
    Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000000997.
    PubMed     Abstract available


  31. KIM I, Oh J, Yoon S, Han MY, et al
    Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea (2004-2019).
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000001000.
    PubMed     Abstract available


  32. ZWEEDIJK BE, Schurink AW, van Dalen T, van Ginhoven TM, et al
    Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green.
    Melanoma Res. 2024 Aug 2. doi: 10.1097/CMR.0000000000000994.
    PubMed     Abstract available


  33. WANG S, Zhou H, Ma Y, Jin S, et al
    A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site.
    Melanoma Res. 2024;34:390-392.
    PubMed    


  34. KIBBIE JJ, Zita SM, Dellavalle RP, Dunnick CA, et al
    The number needed to biopsy for cutaneous melanoma in academic dermatology clinics.
    Melanoma Res. 2024;34:350-354.
    PubMed     Abstract available


  35. ORLANDI E, Ceccuzzi L, Belpinati F, Rodolfo M, et al
    Sex-dependent interaction of PTGS2 with miR-146a as risk factor for melanoma and the impact of sex hormones in gene expression in skin cells.
    Melanoma Res. 2024;34:296-306.
    PubMed     Abstract available


  36. OZLUK AA, Gunenc D, Yildirim SS, Karaca B, et al
    Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature.
    Melanoma Res. 2024;34:335-342.
    PubMed     Abstract available


    July 2024
  37. ZHANG S, Liu Z, Zhu D
    Development and validation of prognostic nomogram in pediatric melanoma: a population-based study.
    Melanoma Res. 2024 Jul 31. doi: 10.1097/CMR.0000000000000993.
    PubMed     Abstract available


  38. ELMES JB, Davis JM, Musselwhite LW, Chiad Z, et al
    Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis.
    Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000992.
    PubMed     Abstract available


  39. TSIMPIDAKIS A, Koumprentziotis IA, Mastoraki E, Plaka M, et al
    Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight.
    Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000991.
    PubMed     Abstract available


  40. CHANDRASEKARAN S, Ling YL, Tang J
    Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States.
    Melanoma Res. 2024 Jul 16. doi: 10.1097/CMR.0000000000000990.
    PubMed     Abstract available


  41. FOKKEN C, Silbern I, Shomroni O, Pan KT, et al
    Interfering with aggregated alpha-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins.
    Melanoma Res. 2024 Jul 2. doi: 10.1097/CMR.0000000000000982.
    PubMed     Abstract available


    June 2024
  42. LOCHRIN SE, Cugliari MK, Yeh R, Shoushtari AN, et al
    Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma.
    Melanoma Res. 2024 Jun 28. doi: 10.1097/CMR.0000000000000988.
    PubMed     Abstract available


  43. DE GIORGI V, Cecchi G, Perillo G, Zuccaro B, et al
    Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical and dermoscopic case study.
    Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000989.
    PubMed     Abstract available


  44. ASHER N, Bar-Hai N, Ben-Betzalel G, Stoff R, et al
    Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy.
    Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000985.
    PubMed     Abstract available


  45. SHEMER M, Shimonovitz M, Furer R, Abu-Abeid A, et al
    Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience.
    Melanoma Res. 2024 Jun 14. doi: 10.1097/CMR.0000000000000986.
    PubMed     Abstract available


  46. BUSTAMANTE P, Coblentz J, Mastromonaco C, Youhnovska E, et al
    Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model.
    Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000964.
    PubMed     Abstract available


  47. LIU H, Jiang H, Shan Q
    Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis.
    Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000980.
    PubMed     Abstract available


  48. LUO P, Guo R, Gao D, Zhang Q, et al
    Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study.
    Melanoma Res. 2024 Jun 5. doi: 10.1097/CMR.0000000000000983.
    PubMed     Abstract available


  49. DINI F, Susini P, Zuccaro B, Nisi G, et al
    Head and neck melanoma: the eyelid region has a better prognosis and easier management: a retrospective survey and systematic review.
    Melanoma Res. 2024 Jun 3. doi: 10.1097/CMR.0000000000000984.
    PubMed     Abstract available


  50. SHAH H, Parisi R, Everdell E, Feustel P, et al
    The effect of COVID-19 on early melanoma detection.
    Melanoma Res. 2024;34:283-284.
    PubMed    


    May 2024
  51. SAMLOWSKI W, Silver MA, Hohlbauch A, Zhang S, et al
    Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma.
    Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000962.
    PubMed     Abstract available


  52. VANDER MIJNSBRUGGE AS, Cerckel J, Dirven I, Tijtgat J, et al
    Regorafenib in patients with pretreated advanced melanoma: a single-center case series.
    Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000977.
    PubMed     Abstract available


  53. INDINI A, Gueli R, Cerati M, Rijavec E, et al
    Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.
    Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000981.
    PubMed     Abstract available


  54. ALBERTINI MR, Zuleger CL, Ranheim EA, Shiyanbola O, et al
    Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.
    Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000975.
    PubMed     Abstract available


    April 2024
  55. GAO Y, Wang Y, Luo Y, Zhang Y, et al
    Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors.
    Melanoma Res. 2024 Apr 22. doi: 10.1097/CMR.0000000000000972.
    PubMed     Abstract available


  56. WU LW, Tao JJ, McDonnell D, Izar B, et al
    Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.
    Melanoma Res. 2024 Apr 18. doi: 10.1097/CMR.0000000000000974.
    PubMed     Abstract available


  57. SUWAJANAKORN D, Lane AM, Go AK, Hartley CD, et al
    Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma.
    Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000971.
    PubMed     Abstract available


  58. HENNEMANN A, Puzenat E, Decreuse M, Vuillier F, et al
    Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
    Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000820.
    PubMed     Abstract available


  59. MAIONE V, Perantoni M, Bettolini L, Bighetti S, et al
    Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients.
    Melanoma Res. 2024 Apr 2. doi: 10.1097/CMR.0000000000000970.
    PubMed     Abstract available


    March 2024
  60. KODALI N, Bhattaru A, Blanchard I, Sharma Y, et al
    Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
    Melanoma Res. 2024 Mar 29. doi: 10.1097/CMR.0000000000000968.
    PubMed     Abstract available


  61. FABRE M, Lamoureux A, Meunier L, Samaran Q, et al
    Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
    Melanoma Res. 2024 Mar 28. doi: 10.1097/CMR.0000000000000963.
    PubMed     Abstract available


  62. NEKKANTI SS, Nusrath S, Jarang R, Rayani BK, et al
    Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity.
    Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000967.
    PubMed     Abstract available


  63. LEROY M, Desmedt E, Deramoudt L, Vasseur M, et al
    Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
    Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000965.
    PubMed     Abstract available


  64. WANG P, Liu T, Zhang Q, Luo P, et al
    Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study.
    Melanoma Res. 2024 Mar 11. doi: 10.1097/CMR.0000000000000960.
    PubMed     Abstract available


  65. NG CA, Luckett T, Mulhern B, Kee D, et al
    What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life.
    Melanoma Res. 2024 Mar 5. doi: 10.1097/CMR.0000000000000961.
    PubMed     Abstract available


    February 2024
  66. DE PINTO G, Mignozzi S, La Vecchia C, Levi F, et al
    Global trends in cutaneous malignant melanoma incidence and mortality.
    Melanoma Res. 2024 Feb 21. doi: 10.1097/CMR.0000000000000959.
    PubMed     Abstract available


  67. TEIXEIRA RJ, de Souza VG, Sorroche BP, Paes VG, et al
    Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio (tNLR) predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
    Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000958.
    PubMed     Abstract available


  68. ZHANG W, Wang S
    Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
    Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000957.
    PubMed     Abstract available


  69. DE SMEDT J, Aura C, Van Kelst S, Janssen L, et al
    Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients.
    Melanoma Res. 2024 Feb 13. doi: 10.1097/CMR.0000000000000929.
    PubMed     Abstract available


  70. DELZENNE G, Boileau M, Jamme P, Farchi O, et al
    Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000955.
    PubMed     Abstract available


  71. ERCAN A, Yalcin CE
    Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000956.
    PubMed     Abstract available


  72. DIAZ MJ, Quach J, Song J, Milanovic S, et al
    Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000938.
    PubMed     Abstract available


  73. GEIGER CE, Mrabet-Dahbi S, Berger I
    The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?
    Melanoma Res. 2024;34:85-87.
    PubMed    


  74. ROSTER K, Thang C, Islam S, Lipner SR, et al
    Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies.
    Melanoma Res. 2024;34:84-88.
    PubMed    


  75. DUARTE R, Trigo F, Luz I, Santos P, et al
    Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report.
    Melanoma Res. 2024;34:76-79.
    PubMed     Abstract available


    January 2024
  76. DAVIDSON TM, Hieken TJ, Glasgow AE, Habermann EB, et al
    Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020.
    Melanoma Res. 2024 Jan 23. doi: 10.1097/CMR.0000000000000953.
    PubMed     Abstract available


  77. KOSTAKI M, Plaka M, Befon A, Dessinioti C, et al
    Simultaneous melanomas in the setting of multiple primary melanomas.
    Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000954.
    PubMed     Abstract available


  78. PARISA S, Amirhossein I, Hamed YS, Javad F, et al
    The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity.
    Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000931.
    PubMed     Abstract available


  79. KO B, Tao K, Brennan L, Rakhade S, et al
    Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
    Melanoma Res. 2024 Jan 5. doi: 10.1097/CMR.0000000000000945.
    PubMed     Abstract available


    December 2023
  80. LOUVEAU B, Reger De Moura C, Jouenne F, Sadoux A, et al
    Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
    Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000950.
    PubMed     Abstract available


  81. YEE J, Rosendahl C, Aoude LG
    The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective.
    Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000951.
    PubMed     Abstract available


  82. ROSHARDT PRIETO NM, Turko P, Zellweger C, Nguyen-Kim TDL, et al
    Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
    Melanoma Res. 2023 Dec 19. doi: 10.1097/CMR.0000000000000952.
    PubMed     Abstract available


  83. YAN J, Wang H, Lu X, Li F, et al
    Development and validation of a nomogram for elderly patients with ulcerative melanoma.
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000940.
    PubMed     Abstract available


  84. BAFALOUKOS D, Kouzis P, Gouveris P, Boukovinas I, et al
    Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter ch
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000949.
    PubMed     Abstract available


  85. RICHTIG E, Nguyen VA, Koelblinger P, Wolf I, et al
    Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
    Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000948.
    PubMed     Abstract available


  86. SWITZER B, Puzanov I, Gandhi S, Repasky EA, et al
    Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity.
    Melanoma Res. 2023 Dec 4. doi: 10.1097/CMR.0000000000000943.
    PubMed     Abstract available


  87. PARISI R, Shah H, Everdell E, Feustel P, et al
    First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma.
    Melanoma Res. 2023;33:555-556.
    PubMed    


  88. CARMONA-ROCHA E, Sullivan I, Yelamos O
    Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response.
    Melanoma Res. 2023;33:553-555.
    PubMed    


  89. TAN SX, Chong S, Rowe C, Claeson M, et al
    pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma.
    Melanoma Res. 2023;33:506-513.
    PubMed     Abstract available


  90. MEYER SN, Simmons E, Studer AC, Rauen KA, et al
    Melanocytic neoplasms in neurofibromatosis type 1: a systematic review.
    Melanoma Res. 2023;33:437-446.
    PubMed     Abstract available


  91. VIGNESWARAN G, Malalasekera W, Smith V, Gibson T, et al
    Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma.
    Melanoma Res. 2023 Dec 1. doi: 10.1097/CMR.0000000000000947.
    PubMed     Abstract available


    November 2023
  92. STAHLIE EHA, Zijlker LP, Wouters MWJM, Schrage YM, et al
    Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
    Melanoma Res. 2023 Nov 28. doi: 10.1097/CMR.0000000000000946.
    PubMed     Abstract available


  93. MEZOLAKI NE, Baltas E, Ocsai HL, Varga A, et al
    Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study.
    Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000935.
    PubMed     Abstract available


  94. KAHLER KC, Debus D, Schley G, Goppner D, et al
    Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
    Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000908.
    PubMed     Abstract available


  95. PAOLINO G, Carugno A, Rongioletti F, Ponzoni M, et al
    Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma.
    Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000942.
    PubMed     Abstract available


  96. CHEN W, Yang C, Chen B, Xi M, et al
    Management of metastatic bone disease of melanoma.
    Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000937.
    PubMed     Abstract available


  97. TAIBO A, Paradela S, Suanzes-Hernandez J, Balboa-Barreiro V, et al
    Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000920.
    PubMed     Abstract available


  98. GAMBICHLER T, Iordanou M, Becker JC, Susok L, et al
    Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000934.
    PubMed     Abstract available


  99. KIM HE, Kim J, Park HK, Lee JB, et al
    Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000939.
    PubMed     Abstract available


  100. BENESCH MGK, Skitzki JJ
    Impact of anesthesia choice in cutaneous melanoma surgery.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000936.
    PubMed     Abstract available


  101. KOHL LM, Sumpter TL
    Melanomas and mast cells: an ambiguous relationship.
    Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000932.
    PubMed     Abstract available


    October 2023
  102. CAO Y, Afzal MZ, Gutmann EJ, Shirai K, et al
    Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
    Melanoma Res. 2023 Oct 13. doi: 10.1097/CMR.0000000000000925.
    PubMed     Abstract available


  103. SADA I, Harada Y, Hiyama T, Mizukami M, et al
    Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
    Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000933.
    PubMed     Abstract available


  104. RUBATTO M, Borriello S, Sciamarrelli N, Pala V, et al
    Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies.
    Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000926.
    PubMed     Abstract available


  105. PHAM JP, Dwyer L, Phan K, Menzies AM, et al
    Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
    Melanoma Res. 2023;33:434-436.
    PubMed    


  106. OZLUK AA, Karateke M, Sanli UA, Karaca B, et al
    Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
    Melanoma Res. 2023;33:417-421.
    PubMed     Abstract available


    September 2023
  107. BOUDREAU MW, Tonogai EJ, Schane CP, Xi MX, et al
    The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.
    Melanoma Res. 2023 Sep 22. doi: 10.1097/CMR.0000000000000927.
    PubMed     Abstract available


  108. SEGURA S, Podlipnik S, Boada A, Marti RM, et al
    Melanoma-specific survival in worse in the elderly: a multicentric cohort study.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000923.
    PubMed     Abstract available


  109. LIN Z, Shen H, Liu X, Ma W, et al
    Recent advances of artificial intelligence in melanoma clinical practice.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000922.
    PubMed     Abstract available


  110. UEMATSU M, Nakajima H, Hosono A, Kiyohara H, et al
    Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
    Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000924.
    PubMed     Abstract available


    August 2023
  111. LUO S, Xie C, Lin N, Lin D, et al
    Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000919.
    PubMed     Abstract available


  112. MATTEI J, Trindade EN, Chedid MF
    Mucosal melanoma: from molecular landscape to current treatment strategies.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000916.
    PubMed     Abstract available


  113. MILEY DR, Andrews-Pfannkoch CM, Pulido JS, Erickson SA, et al
    Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000921.
    PubMed     Abstract available


  114. LIU M, Lan Y, Zhang H, Zhang X, et al
    Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study.
    Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000917.
    PubMed     Abstract available


  115. GJORUP CA, Pires da Silva I, Martin L, Stretch JR, et al
    Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.
    Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000905.
    PubMed     Abstract available


  116. AUGUSTYN K, Joseph J, Patel AB, Razmandi A, et al
    Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
    Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000891.
    PubMed     Abstract available


    July 2023
  117. GLINKINA KA, Teunisse AFAS, Gelmi MC, de Vries J, et al
    Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
    Melanoma Res. 2023 Jul 18. doi: 10.1097/CMR.0000000000000911.
    PubMed     Abstract available


  118. FELICI C, Passarelli A, Cafforio P, Racanelli V, et al
    Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells.
    Melanoma Res. 2023 Jul 12. doi: 10.1097/CMR.0000000000000913.
    PubMed     Abstract available


  119. PELIZZARI G, Bertoli E, Buriolla S, Vitale MG, et al
    Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
    Melanoma Res. 2023 Jul 3. doi: 10.1097/CMR.0000000000000907.
    PubMed     Abstract available


    June 2023
  120. GIRONI LC, Esposto E, Zottarelli F, Giorgione R, et al
    Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients.
    Melanoma Res. 2023 Jun 21. doi: 10.1097/CMR.0000000000000906.
    PubMed     Abstract available


  121. HE K, Hong DS, Ke D, Kebriaei P, et al
    Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
    Melanoma Res. 2023 Jun 16. doi: 10.1097/CMR.0000000000000869.
    PubMed     Abstract available


  122. ASSEFA W, Muluye S, Assefa A, Alemu Y, et al
    A glimpse at locally advanced melanomas in the settings of poverty: pathologists viewpoint.
    Melanoma Res. 2023 Jun 13. doi: 10.1097/CMR.0000000000000909.
    PubMed     Abstract available


  123. KISISTOK J, Christensen DS, Rasmussen MH, Duval L, et al
    Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.
    Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000903.
    PubMed     Abstract available


  124. GARCIA-PEREZ O, Melgar-Vilaplana L, Sifaoui I, Garcia-Bello MA, et al
    Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival.
    Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000904.
    PubMed     Abstract available


  125. AMARA SV, Grbic N, Melson G, Brem CE, et al
    Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection.
    Melanoma Res. 2023 Jun 5. doi: 10.1097/CMR.0000000000000902.
    PubMed     Abstract available


  126. CHERSI F, Conforti C, Zalaudek I, Bazzacco G, et al
    Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
    Melanoma Res. 2023;33:262-263.
    PubMed    


    May 2023
  127. AGNILA DRL, Huda TI, Eakins RA, Patel DN, et al
    Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
    Melanoma Res. 2023 May 23. doi: 10.1097/CMR.0000000000000899.
    PubMed     Abstract available


  128. SHELLENBERGER RA, Gowda S, Kurn H, Albright J, et al
    Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000897.
    PubMed     Abstract available


  129. PHAM JP, On L, Ardolino L, Hurwitz J, et al
    Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000900.
    PubMed     Abstract available


  130. YOO H, Park S, Kim SW
    Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival.
    Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000901.
    PubMed     Abstract available


  131. MATTAVELLI I, Patuzzo R, Galeone C, Pelucchi C, et al
    Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study.
    Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000898.
    PubMed     Abstract available


  132. OGATA D, Nishio S, Hatta N, Kaji T, et al
    Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan.
    Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000894.
    PubMed     Abstract available


    April 2023
  133. DIRVEN I, Vander Mijnsbrugge AS, Mignon S, Tijtgat J, et al
    Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
    Melanoma Res. 2023 Apr 28. doi: 10.1097/CMR.0000000000000895.
    PubMed     Abstract available


  134. WONG CK, Dite GS, Spaeth E, Murphy NM, et al
    Melanoma risk prediction based on a polygenic risk score and clinical risk factors.
    Melanoma Res. 2023 Apr 24. doi: 10.1097/CMR.0000000000000896.
    PubMed     Abstract available


  135. MOHAMMADI A, Najafi S, Amini M, Baradaran B, et al
    B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma.
    Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000890.
    PubMed     Abstract available


  136. STATHAKI MI, Kapsoritakis N, Michelakis D, Anagnostopoulou E, et al
    The impact of sentinel lymph node mapping with hybrid single photon emission computed tomography/computed tomography in patients with melanoma. Comparison to planar radioisotopic lymphoscintigraphy.
    Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000893.
    PubMed     Abstract available


  137. BRUNSGAARD EK, Bowles TL, Asare EA, Grossmann K, et al
    Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
    Melanoma Res. 2023 Apr 5. doi: 10.1097/CMR.0000000000000892.
    PubMed     Abstract available


  138. CYBULSKA-STOPA B, Piejko K, Ostaszewski K, Dziura R, et al
    Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
    Melanoma Res. 2023 Apr 3. doi: 10.1097/CMR.0000000000000885.
    PubMed     Abstract available


  139. LE GOUBEY JB, Sassier M, Nakouri I, De Pontville M, et al
    Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens.
    Melanoma Res. 2023;33:159-161.
    PubMed    


  140. FORTMAN D, Avellan MGP, Hurd D, Schwartz M, et al
    Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients.
    Melanoma Res. 2023;33:136-148.
    PubMed     Abstract available


  141. INGEN-HOUSZ-ORO S, Milpied B, Bensaid B, Elshot Y, et al
    Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.
    Melanoma Res. 2023;33:155-158.
    PubMed     Abstract available


    March 2023
  142. MANZANO JL, Martin-Liberal J, Fernandez-Morales LA, Benitez G, et al
    Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
    Melanoma Res. 2023 Mar 28. doi: 10.1097/CMR.0000000000000888.
    PubMed     Abstract available


  143. VUILLAMY C, Arnault JP, Fumery M, Mortier L, et al
    Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
    Melanoma Res. 2023 Mar 27. doi: 10.1097/CMR.0000000000000878.
    PubMed     Abstract available


  144. YANG H, Zhou J, Li D, Zhou S, et al
    The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis.
    Melanoma Res. 2023 Mar 21. doi: 10.1097/CMR.0000000000000873.
    PubMed     Abstract available


  145. BOILEAU M, Templier C, Massip E, Dehoux C, et al
    Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients.
    Melanoma Res. 2023 Mar 17. doi: 10.1097/CMR.0000000000000889.
    PubMed     Abstract available


  146. PIGNE T, Levy M, Ducharme O, Dutriaux C, et al
    Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
    Melanoma Res. 2023 Mar 15. doi: 10.1097/CMR.0000000000000884.
    PubMed     Abstract available


  147. BOILEAU M, Descarpentries C, Delzenne G, Trentesaux V, et al
    Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000882.
    PubMed     Abstract available


  148. JASSO-SOSA VY, Lino-Silva LS, Escobar-Jimenez MG, Galvan-Bustillos JR, et al
    Prognosis of polypoid melanoma: a comparative study with non-polypoid melanomas.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000886.
    PubMed     Abstract available


  149. BERBERICH C, Mustafa M, Zhuwu Y, Gaa J, et al
    The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography.
    Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000883.
    PubMed     Abstract available


    February 2023
  150. KOMULAINEN J, Siiskonen H, Haimakainen S, Kanasuo E, et al
    Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers.
    Melanoma Res. 2023 Feb 28:e000887. doi: 10.1097/CMR.0000000000000887.
    PubMed     Abstract available


  151. GORLOV IP, Conway K, Edmiston SN, Parrish EA, et al
    Methylation of nonessential genes in cutaneous melanoma - Rule Out hypothesis.
    Melanoma Res. 2023 Feb 20:e000881. doi: 10.1097/CMR.0000000000000881.
    PubMed     Abstract available


  152. JANSSEN L, Van Kelst S, De Smedt J, Terrasson J, et al
    Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy.
    Melanoma Res. 2023;33:84-86.
    PubMed     Abstract available


  153. HUO CW, Gunadasa I, Gkolia P, Shackleton M, et al
    Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases.
    Melanoma Res. 2023;33:58-65.
    PubMed     Abstract available


  154. BETOF WARNER A, Tarhini A, Kang B, Nakasato A, et al
    Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.
    Melanoma Res. 2023;33:38-49.
    PubMed     Abstract available


  155. LI C, Ye Z, Wang Y, Wang G, et al
    High expression of GRB2 associated binding protein 3 mRNA predicts positive prognosis in melanoma.
    Melanoma Res. 2023;33:27-37.
    PubMed     Abstract available


  156. RAO D, Lacroix R, Rooker A, Gomes T, et al
    MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.
    Melanoma Res. 2023;33:12-26.
    PubMed     Abstract available


  157. ZAKRIA D, Brownstone N, Han J, Owji S, et al
    Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy.
    Melanoma Res. 2023;33:80-83.
    PubMed     Abstract available


  158. HOFFMANN F, Frohlich A, Sirokay J, de Vos L, et al
    DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma.
    Melanoma Res. 2023 Feb 1. doi: 10.1097/CMR.0000000000000879.
    PubMed     Abstract available


    January 2023
  159. KOWALIK A, Karpinski P, Markiewicz A, Orlowska-Heitzman J, et al
    Molecular profiling of primary uveal melanoma: results of a Polish cohort.
    Melanoma Res. 2023 Jan 30. doi: 10.1097/CMR.0000000000000874.
    PubMed     Abstract available


  160. PINTO C, Aluai-Cunha C, Santos A
    The human and animals' malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans.
    Melanoma Res. 2023 Jan 20:CMR.0000000000000880.
    PubMed     Abstract available


    December 2022
  161. KANASUO E, Siiskonen H, Haimakainen S, Komulainen J, et al
    Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers.
    Melanoma Res. 2022 Dec 28:CMR.0000000000000870.
    PubMed     Abstract available


  162. GAJANAN K, Daga K, Mullan D, Kosutic D, et al
    New technique for in-continuity axillary and supraclavicular lymphadenectomy for advanced metastatic melanoma using intraoperative image guidance: a case report.
    Melanoma Res. 2022 Dec 28. doi: 10.1097/CMR.0000000000000868.
    PubMed     Abstract available


  163. GARGIULO L, Ibba L, Valenti M, Costanzo A, et al
    Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma.
    Melanoma Res. 2022 Dec 27:CMR.0000000000000875.
    PubMed     Abstract available



  164. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum.
    Melanoma Res. 2022;32:492.
    PubMed    


  165. BORGOGNONI L, Crocetti E, Sestini S, Brandani P, et al
    The importance of mitosis >/=2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy.
    Melanoma Res. 2022;32:469-476.
    PubMed     Abstract available


  166. SMITH JL, Menzies AM, Cohen JV, Mut-Lloret M, et al
    Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.
    Melanoma Res. 2022;32:451-459.
    PubMed     Abstract available


    November 2022
  167. FRANKE V, Stahlie EHA, Klop WMC, Zuur CL, et al
    Talimogene laherparepvec monotherapy for head and neck melanoma patients.
    Melanoma Res. 2022 Nov 29. doi: 10.1097/CMR.0000000000000866.
    PubMed     Abstract available


  168. TRIVEDI DB, Aldulaimi N, Karydis I, Wheater M, et al
    Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature.
    Melanoma Res. 2022 Nov 21. doi: 10.1097/CMR.0000000000000867.
    PubMed     Abstract available


  169. KARTOLO A, Tong J, Yeung C, Kuksis M, et al
    Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients.
    Melanoma Res. 2022 Nov 16. pii: 00008390-990000000-00046.
    PubMed     Abstract available


    October 2022
  170. RAMOS R, Cabre E, Vinyals A, Lorenzo D, et al
    Orthotopic murine xenograft model of uveal melanoma with spontaneous liver metastasis.
    Melanoma Res. 2022 Oct 28. pii: 00008390-990000000-00043.
    PubMed     Abstract available


  171. SHUI IM, Scherrer E, Frederickson A, Li JW, et al
    Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer immunotherapy resistance taskforce anti-PD1 resistance definitions.
    Melanoma Res. 2022 Oct 7. pii: 00008390-990000000-00037.
    PubMed     Abstract available


  172. CAVALLO F, Roccuzzo G, Merli M, Avallone G, et al
    BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome.
    Melanoma Res. 2022;32:390-392.
    PubMed    


  173. BRUGUES A, Ribero S, Pastorino C, Iglesias P, et al
    Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy.
    Melanoma Res. 2022;32:388-390.
    PubMed    


    September 2022
  174. EDMONDS NL, Flores SE, Mahmutovic A, Young SJ, et al
    CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab.
    Melanoma Res. 2022 Sep 28. pii: 00008390-990000000-00041.
    PubMed     Abstract available


  175. FADADU RP, Wei ML
    Ultraviolet A radiation exposure and melanoma: a review.
    Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00039.
    PubMed     Abstract available


  176. MENNENS F, Van Herck Y, Sciot R, Bempt IV, et al
    Melanoma cell plasticity poses diagnostic challenges: a case series.
    Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00038.
    PubMed     Abstract available


  177. TEJEDOR I, Tedbirt B, Carvalho P, Duval-Modeste AB, et al
    Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy.
    Melanoma Res. 2022 Sep 20. pii: 00008390-990000000-00036.
    PubMed     Abstract available


  178. SCHILLER T, Vaisbuch E, Zornitzki T, Kirzhner A, et al
    Adrenal metastatic melanoma first identified during pregnancy: a diagnostic challenge.
    Melanoma Res. 2022 Sep 13. pii: 00008390-990000000-00035.
    PubMed     Abstract available


  179. YIN L, Liu X, Wu J, Yang J, et al
    LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization.
    Melanoma Res. 2022 Sep 9. pii: 00008390-990000000-00034.
    PubMed     Abstract available


    August 2022
  180. COMITO F, Aprile M, Pagani R, Siepe G, et al
    Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.
    Melanoma Res. 2022 Aug 29. pii: 00008390-990000000-00033.
    PubMed     Abstract available


  181. ZHENG YJ, Ho W, Sanlorenzo M, Vujic I, et al
    Melanoma risk during immunomodulating treatment.
    Melanoma Res. 2022 Aug 22. pii: 00008390-990000000-00032.
    PubMed     Abstract available


  182. GRACIA-DARDER I, Carrera C, Alamon-Reig F, Puig S, et al
    Vitamin D deficiency in melanoma patients is associated with worse overall survival: a retrospective cohort study.
    Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00030.
    PubMed     Abstract available


  183. BROWNSTONE N, Marson JW, Zakria D, Farberg A, et al
    Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update.
    Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00031.
    PubMed     Abstract available


  184. LASOCKI A, McArthur GA
    Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status.
    Melanoma Res. 2022 Aug 17. pii: 00008390-990000000-00029.
    PubMed     Abstract available


    July 2022
  185. MANGANA J, Zihler D, Bossart S, Bronnimann D, et al
    Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice.
    Melanoma Res. 2022 Jul 20. pii: 00008390-990000000-00028.
    PubMed     Abstract available


  186. BUJA A, Rugge M, De Luca G, Zorzi M, et al
    Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective.
    Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00027.
    PubMed     Abstract available


  187. FILIPPI F, Serra N, Vigano P, Boeri L, et al
    Fertility preservation for patients with melanoma.
    Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00025.
    PubMed     Abstract available


  188. OSTOJIC N, Radevic T, Kandolf Sekulovic L, Djordjevic B, et al
    Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients.
    Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00026.
    PubMed     Abstract available


  189. KLEE G, Hagelstein V, Kurzhals JK, Zillikens D, et al
    Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
    Melanoma Res. 2022 Jul 19. pii: 00008390-990000000-00024.
    PubMed     Abstract available


  190. LINO-SILVA LS, Zepeda-Najar C, Caro-Sanchez CH, Herrera-Gomez A, et al
    Prognostic significance of tumor budding in melanoma.
    Melanoma Res. 2022 Jul 1. pii: 00008390-990000000-00023.
    PubMed     Abstract available


    June 2022
  191. GONZALEZ-BARRALLO I, Castellon Rubio VE, Medina J, Espana S, et al
    Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
    Melanoma Res. 2022 Jun 27. pii: 00008390-990000000-00022.
    PubMed     Abstract available


  192. TASKAYNATAN H, Gunenc D, On S, Mizrak A, et al
    Immunotherapy-induced granulomatous reaction in patients with melanoma.
    Melanoma Res. 2022 Jun 23. pii: 00008390-990000000-00021.
    PubMed     Abstract available


  193. YU IS, Wee K, Williamson L, Titmuss E, et al
    Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis.
    Melanoma Res. 2022 Jun 17. pii: 00008390-990000000-00020.
    PubMed     Abstract available


  194. SIZOVA M, Camacho V, Sampedro F, Sabate-Llobera A, et al
    Brain metabolic changes in patients with disseminated malignant melanoma under immunotherapy.
    Melanoma Res. 2022 Jun 15. pii: 00008390-990000000-00019.
    PubMed     Abstract available


  195. WEBER JS, Levinson BA, Laino AS, Pavlick AC, et al
    Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.
    Melanoma Res. 2022 Jun 9. pii: 00008390-990000000-00018.
    PubMed     Abstract available


  196. ISMAIL RK, Suijkerbuijk KPM, de Boer A, van Dartel M, et al
    Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.
    Melanoma Res. 2022 Jun 6. pii: 00008390-990000000-00017.
    PubMed     Abstract available


  197. INGEN-HOUSZ-ORO S, Milpied B, Badrignans M, Carrera C, et al
    Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.
    Melanoma Res. 2022;32:205-210.
    PubMed     Abstract available


    May 2022
  198. RODRIGUEZ CASTELLS M, Galisteo Lencastre Veiga C, Fernandez-Morales LA, Ejarque Martinez C, et al
    Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors.
    Melanoma Res. 2022 May 30. pii: 00008390-990000000-00016.
    PubMed     Abstract available


  199. MEYER N, Perol D, Duval-Modeste AB, El Adaoui L, et al
    Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.
    Melanoma Res. 2022 May 27. pii: 00008390-990000000-00015.
    PubMed     Abstract available


  200. MADISON CJ, Heinrich MC, Thompson RF, Yu WY, et al
    Statin use is associated with improved overall survival in patients with melanoma.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00012.
    PubMed     Abstract available


  201. LI AT, Miin Yip J, Choksi H, London K, et al
    Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00013.
    PubMed     Abstract available


  202. DIKA E, Lambertini M, Lauriola M, Veronesi G, et al
    Female melanoma and estrogen receptors expression: an immunohistochemical pilot study.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00010.
    PubMed     Abstract available


  203. SEYED JAFARI SM, Mazinani M, Beutler-Minth V, Lamos C, et al
    Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00011.
    PubMed     Abstract available


  204. HANNARICI Z, Yilmaz A, Buyukbayram ME, Tekin SB, et al
    Reply to John L. Frater's letter to the editor entitled Use of laboratory hematology data in melanoma research: comments on 'A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio'.
    Melanoma Res. 2022 May 13. pii: 00008390-990000000-00014.
    PubMed    


  205. WOLFE Z, Friedland JC, Ginn S, Blackham A, et al
    Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
    Melanoma Res. 2022 May 12. pii: 00008390-990000000-00009.
    PubMed     Abstract available


    April 2022
  206. MULDER EEAP, Damman J, Verver D, van der Veldt AAM, et al
    Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma.
    Melanoma Res. 2022 Apr 21. pii: 00008390-990000000-00008.
    PubMed     Abstract available


  207. SCHMELTER V, Hofmann T, Schneider F, Weber C, et al
    Robotic CyberKnife radiosurgery for small choroidal melanomas.
    Melanoma Res. 2022 Apr 8. pii: 00008390-990000000-00007.
    PubMed     Abstract available


  208. FRATER JL
    Use of laboratory hematology data in melanoma research: comments on "A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio" Melanoma Res 2021; 31:566-574.
    Melanoma Res. 2022;32:136.
    PubMed    


  209. O'DAY R, Grantham M, Thaung C, Szlosarek P, et al
    Tetrasomy of chromosomes 3 and 8 in a young male with choroidal melanoma.
    Melanoma Res. 2022;32:134-135.
    PubMed    


  210. GAMBICHLER T, Susok L
    Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma.
    Melanoma Res. 2022;32:132-133.
    PubMed    


  211. FARRELL J, Stewart TJ, Rosen R
    Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort.
    Melanoma Res. 2022;32:130-131.
    PubMed    


  212. MIECZKOWSKA K, Jacob J, Paoluzzi L, Papalezova KT, et al
    Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors.
    Melanoma Res. 2022;32:128-129.
    PubMed    


  213. KROMER C, Vlahova LD, Julius K, Schnabel V, et al
    Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib.
    Melanoma Res. 2022;32:124-127.
    PubMed    


  214. MODI S, Gibson T, Vigneswaran G, Patel S, et al
    Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
    Melanoma Res. 2022;32:103-111.
    PubMed     Abstract available


  215. WISCO OJ, Marson JW, Litchman GH, Brownstone N, et al
    Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
    Melanoma Res. 2022;32:98-102.
    PubMed     Abstract available


  216. WACH MM, Subjeck JR, Wang XY, Repasky E, et al
    Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients.
    Melanoma Res. 2022;32:88-97.
    PubMed     Abstract available


  217. HILL MV, Vidri RJ, Deng M, Handorf E, et al
    Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma.
    Melanoma Res. 2022;32:79-87.
    PubMed     Abstract available


  218. YIN G, Guo W, Huang Z, Chen X, et al
    Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis.
    Melanoma Res. 2022;32:71-78.
    PubMed     Abstract available


    March 2022
  219. AWADA G, Schwarze JK, Tijtgat J, Fasolino G, et al
    A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00001.
    PubMed     Abstract available


  220. WANG CY, Zoungas S, Voskoboynik M, Mar V, et al
    Cardiovascular disease and malignant melanoma.
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00004.
    PubMed     Abstract available


  221. YANO M, Nasu K, Yasuda M, Katoh T, et al
    Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s).
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00002.
    PubMed     Abstract available


  222. LAUWYCK J, Schreuer M, Meric de Bellefon L, Van Erps J, et al
    Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports.
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00003.
    PubMed     Abstract available


  223. FU XL, Feng LP, Yu HR, Du L, et al
    Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials.
    Melanoma Res. 2022 Mar 29. pii: 00008390-990000000-00005.
    PubMed     Abstract available


  224. PEDERSEN S, Moller S, Donia M, Persson GF, et al
    Real-world data on melanoma brain metastases and survival outcome.
    Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98978.
    PubMed     Abstract available


  225. XU J, Ou R, Nie G, Wen J, et al
    LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression.
    Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98977.
    PubMed     Abstract available


  226. MCCANN B, Higgins M, Kok DL, Hong W, et al
    Long-term control of melanoma adrenal metastasis treated with radiotherapy.
    Melanoma Res. 2022 Mar 7. pii: 00008390-900000000-98976.
    PubMed     Abstract available


    February 2022
  227. HOTZ MJ, O'Halloran EA, Hill MV, Hayden K, et al
    Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.
    Melanoma Res. 2022 Feb 24. pii: 00008390-900000000-98979.
    PubMed     Abstract available


  228. ZHOU L, Yang Y, Si L, Chi Z, et al
    Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
    Melanoma Res. 2022 Feb 20. pii: 00008390-900000000-98980.
    PubMed     Abstract available


  229. STECKLER AM, Francis JH, Shoushtari AN, Abramson DH, et al
    Uveal melanoma metastatic at initial diagnosis: a case series.
    Melanoma Res. 2022 Feb 11. pii: 00008390-900000000-98981.
    PubMed     Abstract available


  230. DUNJIC M, Lukic N, Djordjevic B, Uzelac B, et al
    GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients.
    Melanoma Res. 2022;32:11-17.
    PubMed     Abstract available


  231. LEE J, Jin YJ, Lee MS, Lee H, et al
    Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization.
    Melanoma Res. 2022;32:1-10.
    PubMed     Abstract available


  232. KIM YH, Kim Y, Park TJ, Kang HY, et al
    Ponatinib-induced eruptive nevi and melanocytic proliferation.
    Melanoma Res. 2022;32:59-62.
    PubMed     Abstract available


    December 2021
  233. SUN S, Shi R, Xu L, Sun F, et al
    Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology.
    Melanoma Res. 2021 Dec 3. pii: 00008390-900000000-98987.
    PubMed     Abstract available


  234. JANOWSKA A, Oranges T, Iannone M, Davini G, et al
    Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series.
    Melanoma Res. 2021;31:561-565.
    PubMed     Abstract available


  235. YE JY, Yu C, Husman T, Chen B, et al
    Novel strategy for applying hierarchical density-based spatial clustering of applications with noise towards spectroscopic analysis and detection of melanocytic lesions.
    Melanoma Res. 2021;31:526-532.
    PubMed     Abstract available


    November 2021
  236. CAKIR OO, Pozzi E, Castiglione F, Freeman A, et al
    Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines.
    Melanoma Res. 2021 Nov 24. pii: 00008390-900000000-98989.
    PubMed     Abstract available


  237. DAVIDSON TM, Markovic SN, Dimou A
    The immunologic balance: three cases of rituximab-associated melanoma.
    Melanoma Res. 2021 Nov 15. pii: 00008390-900000000-98990.
    PubMed     Abstract available


  238. SAH VR, Karlsson J, Jespersen H, Lindberg MF, et al
    Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma.
    Melanoma Res. 2021 Nov 5. pii: 00008390-900000000-98991.
    PubMed     Abstract available


  239. DE GIORGI V, Gemignani A, Scarfi F, Trane L, et al
    Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon?
    Melanoma Res. 2021 Nov 1. pii: 00008390-900000000-98993.
    PubMed     Abstract available


  240. JAN WILLEM RAUWERDINK D, van Persijn van Meerten E, van der Hage J, Kapiteijn E, et al
    Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma.
    Melanoma Res. 2021 Nov 1. pii: 00008390-900000000-98992.
    PubMed     Abstract available


    October 2021
  241. PARIETTI M, Marra E, Ribero S, Abate SO, et al
    Leptomeningeal dissemination as a first sign of progression in metastatic melanoma: a diagnostic lesson.
    Melanoma Res. 2021 Oct 22. pii: 00008390-900000000-98994.
    PubMed     Abstract available


  242. MOGLIA A, Cerri A, Moglia A, Berchiolli R, et al
    Machine learning for the identification of decision boundaries during the transition from radial to vertical growth phase superficial spreading melanomas.
    Melanoma Res. 2021 Oct 21. pii: 00008390-900000000-98995.
    PubMed     Abstract available


  243. MANTIA CM, Werner L, Stwalley B, Ritchings C, et al
    Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.
    Melanoma Res. 2021 Oct 20. pii: 00008390-900000000-98997.
    PubMed     Abstract available


  244. GARGIULO L, Chiara Tronconi M, Grimaudo MS, Pavia G, et al
    Connective tissue panniculitis and vitiligo in a with patient stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy.
    Melanoma Res. 2021 Oct 5. pii: 00008390-900000000-98999.
    PubMed     Abstract available


  245. JANOWSKA A, Oranges T, Iannone M, Romanelli M, et al
    Seborrheic keratosis-like melanoma: a diagnostic challenge.
    Melanoma Res. 2021;31:407-412.
    PubMed     Abstract available


  246. TULOKAS SKA, Kohtamaki LM, Makela SP, Juteau S, et al
    Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
    Melanoma Res. 2021;31:456-463.
    PubMed     Abstract available


    September 2021
  247. HANNARICI Z, Yilmaz A, Buyukbayram ME, Tekin SB, et al
    A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio.
    Melanoma Res. 2021 Sep 23. pii: 00008390-900000000-99001.
    PubMed     Abstract available


  248. FIDANZI C, Manzo Margiotta F, Spinelli C, Janowska A, et al
    Risk factors in pediatric melanoma: a retrospective study of 39 cases.
    Melanoma Res. 2021 Sep 23. pii: 00008390-900000000-99000.
    PubMed     Abstract available


  249. AMAGAI R, Muto Y, Kato H, Matsushita S, et al
    Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases.
    Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99006.
    PubMed     Abstract available


  250. FONSECA M, Soares R, Coelho P
    Lower melanoma pulmonary metastatic burden in obese mice: role of FGF-21.
    Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99005.
    PubMed     Abstract available


  251. LAN S, Cui Z, Yin Q, Liu Z, et al
    Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon alpha-2b.
    Melanoma Res. 2021 Sep 13. pii: 00008390-900000000-99004.
    PubMed     Abstract available


  252. CHEN M, Li Q, Chen W, Bi J, et al
    Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis.
    Melanoma Res. 2021 Sep 7. pii: 00008390-900000000-99008.
    PubMed     Abstract available


  253. SHI CJ, Xu SM, Han Y, Zhou R, et al
    Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
    Melanoma Res. 2021 Sep 3. pii: 00008390-900000000-99009.
    PubMed     Abstract available


    August 2021
  254. AVALLONE G, Astrua C, Fava P, Tonella L, et al
    Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era.
    Melanoma Res. 2021 Aug 27. pii: 00008390-900000000-99010.
    PubMed    


  255. FARINAZZO E, Zelin E, Agozzino M, Papa G, et al
    Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99016.
    PubMed     Abstract available


  256. GULIKERS JL, Croes S, Schreurs MJW, Litjens EJR, et al
    Nivolumab exposure in a hemodialysis patient with metastatic melanoma.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99015.
    PubMed     Abstract available


  257. INDINI A, Costa S, Ierardi AM, Rijavec E, et al
    COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99014.
    PubMed     Abstract available


  258. SCHNEIDER S, Alezra E, Yacoub M, Ducharme O, et al
    Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99013.
    PubMed     Abstract available


  259. CHO KK, Cust AE, Foo YM, Long GV, et al
    Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99012.
    PubMed     Abstract available


  260. SILVA CTX, Saddi VA, Silva KSFE, Sugita DM, et al
    Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma.
    Melanoma Res. 2021 Aug 23. pii: 00008390-900000000-99011.
    PubMed     Abstract available


  261. GE Y, Che X, Gao X, Zhao S, et al
    Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review.
    Melanoma Res. 2021 Aug 17. pii: 00008390-900000000-99017.
    PubMed     Abstract available


  262. CULLEN GD, Finnes HD, Markovic SN, Volcheck GW, et al
    Successful encorafenib desensitization in a patient with recurrent metastatic melanoma.
    Melanoma Res. 2021;31:402-404.
    PubMed     Abstract available


  263. ADAMS AM, Chick RC, Vreeland TJ, Clifton GT, et al
    Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
    Melanoma Res. 2021;31:378-388.
    PubMed     Abstract available


  264. XIAO M, Tang N, Yan Y, Li Z, et al
    Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells.
    Melanoma Res. 2021;31:309-318.
    PubMed     Abstract available


  265. PIKKEL YY, Duek OS, Ben Naftali Y, Link Y, et al
    Hidden in plain sight: the (other) danger of COVID-19.
    Melanoma Res. 2021;31:389-392.
    PubMed     Abstract available


    July 2021
  266. KLEE G, Kurzhals J, Hagelstein V, Zillikens D, et al
    Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure.
    Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99021.
    PubMed     Abstract available


  267. TORRICELLI C, Carron J, Carvalho BF, Macedo LT, et al
    Influence of IL1B (rs16944) and IL1R2 (rs4141134) polymorphisms on aggressiveness and prognosis of cutaneous melanoma.
    Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99020.
    PubMed     Abstract available


  268. MONDAL SK, Whiteside TL
    Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression.
    Melanoma Res. 2021 Jul 19. pii: 00008390-900000000-99018.
    PubMed     Abstract available


    June 2021
  269. SANGSTER AB, Chang-McDonald B, Patel J, Bockett N, et al
    Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma.
    Melanoma Res. 2021 Jun 10. pii: 00008390-900000000-99027.
    PubMed     Abstract available


  270. MANNING A, Rassie K, Rivalland G
    A case of hyperprolactinaemia in a patient with metastatic melanoma.
    Melanoma Res. 2021;31:277-279.
    PubMed     Abstract available


  271. TIJTGAT J, Schwarze JK, Awada G, Neyns B, et al
    Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy.
    Melanoma Res. 2021;31:272-276.
    PubMed     Abstract available


  272. HOLSTEAD RG, Kartolo BA, Hopman WM, Baetz TD, et al
    Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors.
    Melanoma Res. 2021;31:258-263.
    PubMed     Abstract available


  273. FRELAU A, Jali E, Campillo-Gimenez B, Pracht M, et al
    Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies.
    Melanoma Res. 2021;31:208-217.
    PubMed     Abstract available


  274. SANCHEZ JN, Subramanian C, Chanda M, Shanguan G, et al
    A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.
    Melanoma Res. 2021;31:197-207.
    PubMed     Abstract available


    May 2021
  275. HE H, Qiao B, Guo S, Cui H, et al
    Induction of T helper 17 cell response by interleukin-7 in patients with primary cutaneous melanoma.
    Melanoma Res. 2021 May 28. pii: 00008390-900000000-99031.
    PubMed     Abstract available


  276. KHULLAR K, Hanft S, Mehnert JM, Weiner JP, et al
    Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib.
    Melanoma Res. 2021 May 28. pii: 00008390-900000000-99030.
    PubMed     Abstract available


  277. LAUWYCK J, Beckwee A, Santens A, Schwarze JK, et al
    C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting.
    Melanoma Res. 2021 May 28. pii: 00008390-900000000-99028.
    PubMed     Abstract available


  278. TACAR SY, Selcukbiricik F, Yilmaz M, Erturk K, et al
    Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99038.
    PubMed     Abstract available


  279. WILSON T, Taylor H, Winter H, Herbert C, et al
    Sequential immunotherapy in melanoma: is it a realistic alternative to dual immunotherapy?
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99037.
    PubMed     Abstract available


  280. HARDIE CM, Allouni A, Edwards S, Ahmed N, et al
    PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99036.
    PubMed     Abstract available


  281. READ RL, Thompson JF
    The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99035.
    PubMed     Abstract available


  282. ZHAO Y, Huang C
    The role of osteopontin in the development and metastasis of melanoma.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99034.
    PubMed     Abstract available


  283. MALISSEN N, Farvacque G, Duconseil P, Birnbaum DJ, et al
    Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99033.
    PubMed     Abstract available


  284. YANG LX, Guo HB, Liu SY, Feng HP, et al
    ETS1 promoted cell growth, metastasis and epithelial-mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression.
    Melanoma Res. 2021 May 25. pii: 00008390-900000000-99032.
    PubMed     Abstract available


  285. WU X, Yan J, Yu J, Cheng Z, et al
    Clinical significance of CCNE1 copy number gain in acral melanoma patients.
    Melanoma Res. 2021 May 6. pii: 00008390-900000000-99040.
    PubMed     Abstract available


  286. BONHOURE A, Henry L, Morille M, Aissaoui N, et al
    Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells.
    Melanoma Res. 2021 May 6. pii: 00008390-900000000-99039.
    PubMed     Abstract available


    April 2021
  287. TREMBATH DG, Ivanova A, Krauze MT, Kirkwood JM, et al
    Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases.
    Melanoma Res. 2021 Apr 12. pii: 00008390-900000000-99043.
    PubMed     Abstract available


  288. LEENEMAN B, Blommestein HM, Coupe VMH, Hendriks MP, et al
    Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands.
    Melanoma Res. 2021 Apr 12. pii: 00008390-900000000-99042.
    PubMed     Abstract available


  289. MOSCHOS SJ, Eroglu Z, Khushalani NI, Kendra KL, et al
    Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
    Melanoma Res. 2021;31:162-172.
    PubMed     Abstract available


    March 2021
  290. THOMPSON JF, Saw RPM, Dalton JM, Stretch JR, et al
    Treatment of in-transit melanoma metastases using intralesional PV-10.
    Melanoma Res. 2021 Mar 18. pii: 00008390-900000000-99046.
    PubMed     Abstract available


  291. SHAH P, Punekar SR, Pavlick AC
    Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.
    Melanoma Res. 2021 Mar 18. pii: 00008390-900000000-99045.
    PubMed     Abstract available


  292. KOHTAMAKI LM, Hernberg M, Jaakkola M, Makela S, et al
    BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients.
    Melanoma Res. 2021 Mar 5. pii: 00008390-900000000-99047.
    PubMed     Abstract available


    February 2021
  293. WESTON GK, Jeong HS, Mu EW, Polsky D, et al
    Impact of COVID-19 on melanoma diagnosis.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99056.
    PubMed    


  294. LEJEUNE FJ, Storkus WJ, Riley PA
    Thirty years of therapeutic innovation in melanoma research.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99055.
    PubMed    


  295. OLOFSSON BAGGE R, Ny L, Ascierto PA, Hodi FS, et al
    The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99054.
    PubMed     Abstract available


  296. SARKAR M, Bhuniya A, Ghosh S, Sarkar A, et al
    Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99052.
    PubMed     Abstract available


  297. DOMINGUEZ-VARELA IA, Ancona-Lezama DA, Dalvin LA, Perez-Ramos EE, et al
    Choroidal melanoma treatment in times of coronavirus disease 2019.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99051.
    PubMed    


  298. KERTYS M, Grendar M, Horak V, Zidekova N, et al
    Metabolomic characterisation of progression and spontaneous regression of melanoma in the melanoma-bearing Libechov minipig model.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99050.
    PubMed     Abstract available


  299. ZHANG X, Su MW, Cheng Y, Martinka M, et al
    Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma.
    Melanoma Res. 2021 Feb 18. pii: 00008390-900000000-99049.
    PubMed     Abstract available


  300. RANTALA ES, Kivela TT, Hernberg MM
    Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma.
    Melanoma Res. 2021 Feb 15. pii: 00008390-900000000-99057.
    PubMed     Abstract available


  301. MILLAN-ESTEBAN D, Garcia-Casado Z, Manrique-Silva E, Kumar R, et al
    KIT mutational status does not constitute an independent prognostic marker in cutaneous melanoma. A study on 688 Spanish patients.
    Melanoma Res. 2021;31:101-103.
    PubMed    


  302. ISMAIL RK, Sikkes NO, Wouters MWJM, Hilarius DL, et al
    Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases.
    Melanoma Res. 2021;31:58-66.
    PubMed     Abstract available


    January 2021
  303. ZHANG T, Li Q, Wang Q, Wang H, et al
    Diagnostic and prognostic value of heat shock protein 90alpha in malignant melanoma.
    Melanoma Res. 2021 Jan 22. pii: 00008390-900000000-99059.
    PubMed     Abstract available


  304. BENINATO T, Fuca G, Di Guardo L, Vetrano I, et al
    Immune-related Bell's palsy in melanoma patients treated with immune checkpoint inhibitors.
    Melanoma Res. 2021 Jan 22. pii: 00008390-900000000-99058.
    PubMed     Abstract available


    December 2020
  305. LUO X, Xu Y, Li Y, Zhang G, et al
    BAP1 deletion abrogates growth and metastasis of murine cutaneous melanoma.
    Melanoma Res. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  306. ZAFAR FS, Richey P, Okereke U, Milhem M, et al
    Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.
    Melanoma Res. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  307. HOLMAN BN, Van Gulick RJ, Amato CM, MacBeth ML, et al
    Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas.
    Melanoma Res. 2020;30:562-573.
    PubMed     Abstract available


  308. MIKKELSEN LH, Maag E, Andersen MK, Kruhoffer M, et al
    The molecular profile of mucosal melanoma.
    Melanoma Res. 2020;30:533-542.
    PubMed     Abstract available



  309. Paradox in melanoma: more patients fewer publications: Retraction.
    Melanoma Res. 2020;30:632.
    PubMed    


  310. IPENBURG NA, van der Hage JA, Newton-Bishop JA, Harland M, et al
    Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations.
    Melanoma Res. 2020;30:630-631.
    PubMed    


  311. VELTER C, Sakkal M, Robert C
    Bariatric surgery in a patient treated with targeted therapies for metastatic melanoma: a case report.
    Melanoma Res. 2020;30:629-630.
    PubMed    


  312. AYAZ T, Ramachandran V, Loya A, Patel S, et al
    Impact of marital status on survival in cutaneous melanoma.
    Melanoma Res. 2020;30:628-629.
    PubMed    


  313. MARCAILLOU M, Linder C, Chaltiel L, Sibaud V, et al
    PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma.
    Melanoma Res. 2020;30:580-589.
    PubMed     Abstract available


    November 2020
  314. MURRIA ESTAL R, de Unamuno Bustos B, Perez Simo G, Simarro Farinos J, et al
    MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas.
    Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000709.
    PubMed     Abstract available


  315. NUNEZ ABAD M, Saval Victoria A, Franco La Rosa M, Berrocal A, et al
    Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report.
    Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000710.
    PubMed     Abstract available


  316. HODI FS, Chapman PB, Sznol M, Lao CD, et al
    Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
    Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000708.
    PubMed     Abstract available


  317. DUDDA M, Mann C, Heinz J, Schmidgen I, et al
    Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature.
    Melanoma Res. 2020 Nov 23. doi: 10.1097/CMR.0000000000000703.
    PubMed     Abstract available


  318. LIU WK, Naban N, Kaul A, Patel N, et al
    Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma.
    Melanoma Res. 2020 Nov 13. doi: 10.1097/CMR.0000000000000706.
    PubMed     Abstract available


  319. BAO R, Surriga O, Olson DJ, Allred JB, et al
    Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target.
    Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000701.
    PubMed     Abstract available


  320. ANDERSON TS, Wooster AL, La-Beck NM, Saha D, et al
    Antibody-drug conjugates: an evolving approach for melanoma treatment.
    Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000702.
    PubMed     Abstract available


  321. CYBULSKA-STOPA B, Zietek M, Kaminska-Winciorek G, Czarnecka AM, et al
    Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.
    Melanoma Res. 2020 Nov 6. doi: 10.1097/CMR.0000000000000705.
    PubMed     Abstract available


  322. BENIEY M, Tran A, Boulva K
    Mapping sentinel lymph nodes in cutaneous melanoma: a vast array of perioperative imaging modalities.
    Melanoma Res. 2020 Nov 5. doi: 10.1097/CMR.0000000000000704.
    PubMed     Abstract available


    October 2020
  323. FARRICHA V, Quaglino P, Brizio M, de Terlizzi F, et al
    Safety and efficacy of electrochemotherapy in a series of patients with nonmetastasized primary or recurrent anorectal malignant melanoma.
    Melanoma Res. 2020 Oct 8. doi: 10.1097/CMR.0000000000000699.
    PubMed     Abstract available


    September 2020
  324. LEE S, Suh HB, Choi SJ, Kang J, et al
    Identification of prognostic mRNAs in metastatic cutaneous melanoma.
    Melanoma Res. 2020 Sep 29. doi: 10.1097/CMR.0000000000000697.
    PubMed     Abstract available


  325. MATTEI J, Ballhausen A, Bassett R, Shephard M, et al
    A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma.
    Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000694.
    PubMed     Abstract available


  326. CHANG LW, Badal B, Lu CJ, Solovyov A, et al
    An integrative approach identifies dysregulated long non-coding RNAs as microRNA decoys during nevus to melanoma transformation.
    Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000695.
    PubMed     Abstract available


  327. BYRON Y, Nott L, Shackleton M
    Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass.
    Melanoma Res. 2020 Sep 21. doi: 10.1097/CMR.0000000000000696.
    PubMed    


    April 2020
  328. ROS-MONTANA J, Saoudi-Gonzalez N, Ortiz-Velez C, Munoz-Couselo E, et al
    The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.
    Melanoma Res. 2020;30:209-212.
    PubMed     Abstract available


  329. TRUONG A, Hyngstrom JR, Andtbacka RHI, Noyes RD, et al
    Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status.
    Melanoma Res. 2020;30:173-178.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.